Literature DB >> 22893874

A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier.

Joong Ho Bae1, Joo Hyun Sohn, Hye Soon Lee, Hye Sun Park, Yil Sik Hyun, Tae Yeob Kim, Chang Soo Eun, Yong Cheol Jeon, Dong Soo Han.   

Abstract

Hepatitis B virus (HBV) may be reactivated after chemotherapy or immunosuppressive therapy, and therefore administration of antiviral agents before such treatment is recommended. Most reported cases of reactivation are associated with high doses of immunosuppressive agents or combination therapy. We present a case of a previously inactive HBV carrier with an acute severe flare-up during a long-term, very-low-dose (2.5 mg/day) steroid treatment for rheumatoid arthritis. We suggest that even a minimal dose of single-regimen oral steroid can cause reactivation of indolent, inactive HBV.

Entities:  

Keywords:  Hepatitis B virus; Liver failure; Steroids; Virus activation

Mesh:

Substances:

Year:  2012        PMID: 22893874      PMCID: PMC3415881          DOI: 10.3350/cmh.2012.18.2.225

Source DB:  PubMed          Journal:  Clin Mol Hepatol        ISSN: 2287-2728


  19 in total

Review 1.  Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.

Authors:  R P Perrillo
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

Review 2.  The difficulties of managing severe hepatitis B virus reactivation.

Authors:  Bruno Roche; Didier Samuel
Journal:  Liver Int       Date:  2011-01       Impact factor: 5.828

3.  Hepatitis B virus DNA contains a glucocorticoid-responsive element.

Authors:  R Tur-Kaspa; R D Burk; Y Shaul; D A Shafritz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

Review 4.  Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue.

Authors:  Sandro Vento; Francesca Cainelli; Maria Serena Longhi
Journal:  Lancet Oncol       Date:  2002-06       Impact factor: 41.316

5.  Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

Authors:  George K K Lau; Harry H Y Yiu; Daniel Y T Fong; Hoi-Ching Cheng; Wing-Yan Au; Lydia S F Lai; Micheal Cheung; Hai-Ying Zhang; Albert Lie; Roger Ngan; Raymond Liang
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

Review 6.  Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.

Authors:  L H Calabrese; N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

7.  Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis.

Authors:  K C Lam; C L Lai; C Trepo; P C Wu
Journal:  N Engl J Med       Date:  1981-02-12       Impact factor: 91.245

8.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

Review 9.  Viral hepatitis B.

Authors:  Ching Lung Lai; Vlad Ratziu; Man-Fung Yuen; Thierry Poynard
Journal:  Lancet       Date:  2003-12-20       Impact factor: 79.321

Review 10.  Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy.

Authors:  Giuseppe Rossi
Journal:  Leuk Lymphoma       Date:  2003-05
View more
  7 in total

Review 1.  Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.

Authors:  Pilar López-Serrano; Elsa de la Fuente Briongos; Elisa Carrera Alonso; Jose Lázaro Pérez-Calle; Conrado Fernández Rodríguez
Journal:  World J Hepatol       Date:  2015-03-27

2.  Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.

Authors:  Mary Jane Burton; Jeffrey R Curtis; Shuo Yang; Lang Chen; Jasvinder A Singh; Ted R Mikuls; Kevin L Winthrop; John W Baddley
Journal:  Arthritis Res Ther       Date:  2015-05-22       Impact factor: 5.156

Review 3.  Treatment of rheumatic diseases and hepatitis B virus coinfection.

Authors:  Anna Felis-Giemza; Marzena Olesińska; Katarzyna Świerkocka; Ewa Więsik-Szewczyk; Ewa Haładyj
Journal:  Rheumatol Int       Date:  2014-12-31       Impact factor: 2.631

4.  Hepatitis B virus reactivation with corticosteroid therapy in patients with adrenal insufficiency.

Authors:  Masako Hatano; Toshihide Mimura; Akira Shimada; Mitsuhiko Noda; Shigehiro Katayama
Journal:  Endocrinol Diabetes Metab       Date:  2019-05-09

Review 5.  Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.

Authors:  Dandan Xuan; Yiqi Yu; Linyun Shao; Jiali Wang; Wenhong Zhang; Hejian Zou
Journal:  Clin Rheumatol       Date:  2013-12-11       Impact factor: 2.980

Review 6.  Should we consider patients with coexistent hepatitis B or C infection for orthotopic heart transplantation?

Authors:  Baskar Sekar; Pippa J Newton; Simon G Williams; Steven M Shaw
Journal:  J Transplant       Date:  2013-11-07

7.  Case reports of latent HBV hepatitis in patients after neurosurgical treatment for hypothalamic and pituitary tumors.

Authors:  Kuniyasu Niizuma; Yoshikazu Ogawa; Takayuki Kogure; Teiji Tominaga
Journal:  BMC Infect Dis       Date:  2020-03-18       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.